Theravance seeks $86.3 million
This article was originally published in Scrip
Executive Summary
Theravance expects to raise $86.3 million for drug development and corporate purposes, including repaying debt. The Nasdaq-listed US firm will offer 7.5 million shares at $11.50 each.